摘要
目的:探讨国产奥氮平治疗老年精神分裂症的疗效和安全性。方法:将64例符合中国精神障碍分类与诊断标准第3版(CCMD-3)的老年精神分裂症患者随机分成两组,分别给予奥氮平(治疗组,32例)和利培酮(对照组,32例)治疗,疗程8周。采用阳性与阴性综合征量表(PANSS)及副反应量表(TESS)评定疗效和不良反应。结果:奥氮平组显效率68.8%、有效率87.5%,利培酮组分别为65.6%、84.4%。两组间显效率(χ2=0.07、P>0.05)及有效率(χ2=0.13,P>0.05)的差异均无统计学意义。两组治疗后各时点PANSS总分,阳性症状、阴性症状和一般病理症状各项分值均低于治疗前,而治疗后各时点组间差异无统计学意义(P>0.05)。不良反应方面:奥氮平组体重增加比例高于利培酮组;利培酮锥体外系不良反应高于奥氮平组,两组差异均有统计学意义(χ2=4.01,P<0.05;χ2=4.27,P<0.05)。结论:国产奥氮平与利培酮治疗老年精神分裂症疗效均好,奥氮平组体重增加较多,利培酮组锥体外系不良反应较多。
Objective：To investigate the efficacy and safety of domestic olanzapine in treatment of patients with geriatric schizophrenia.Methods：A total of 64 patients（met the criteria of Chinese classification of mental disorders,3rd edition for geriatric schizophrenia）were randomly assigned to two groupS treated with olanzapine （n=32） and risperidone （n=32）for 8 weeks respectively. The positive and negative syndrome scale （PANSS） and treatment emergent symptoms scale （TESS） were used to evaluate the efficacy and side effects.Results：The responsive rate and effecitive rate were 68.8% and 87.5% reapectively in olanzapine group and 65.6% and 84.4% in risperidone group. There was no significant difference on the responsive rate and effecitive rate between the two groups. The total factor and factors scores of PANSS were significantly lower after treatment in both groups （P〈0.05）.But there were no significant difference between the two groups （P〉0.05）. Olanzapine was associated with more weight gain and risperidone with more EPS （extrapyramidal syndrome） （18.8% vs 3.1%,χ2=4.01,P〈0.05;6.3% vs 25.0%,χ2=4.27,P〈0.05）.Conclusion：Both domestic olanzapine and risperidone are effective for patients with geriatric schizophrenia. Olanzapine is associated with more weight gain and risperidone with more EPS.
出处
《医药世界》
2009年第10期583-585,共3页
Medicine World
